Table 1 Comparison of features of TICORA, BeSt, and Corrona T2T with EULAR recommendations[12]
TICORA | BeSt | Corrona T2T | EULAR | |
|---|---|---|---|---|
Mandated acceleration | Yes | Yes | Yes | Yes |
Biologics accessible | No | Yes | Yes | Yes |
Predefined acceleration order of therapeutic options | Yes | Yes | No | No |
Biologic prevalence in RA population ≥20% | No | No | Yes | No |
Unique cost-effectiveness climate | Yes | Yes | Yes | Yes |